Product life cycle patterns for pharmaceuticals and their impact on R&D profitability of late mover products

International Business Review

Volumn 9, Issue 6, 2000, Pages 703-725

  Bauer, Hans H ^a   Fischer, Marc ^a  

^a UNIVERSITY OF MANNHEIM   (Germany)

Author keywords

Cluster analysis; Product life cycle theory; R D profitability; Simulation

Indexed keywords

EID: 0034369884     PISSN: 09695931     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0969-5931(00)00028-7     Document Type: Article

References (66)

1. Alberts, W. W., & McTaggert, J. M. (1984). Value based strategic investment planning. Interfaces, January-February, 138-151.
2. Baber, W. R., & Kang, S.-H. (1996). Estimates of economic rates of return for the U.S. phamaceutical industry, 1976-1987. Journal of Accounting and Public Policy, 15, 327-346.
3. Barwise, P. (1995). Good empirical generalizations [special issue on empirical generalizations in marketing]. Marketing Science, 14, G29-G35.
4. Bass, F. M. (1995). Empirical generalizations and marketing science: A personal view [special issue on empirical generalizations in marketing]. Marketing Science, 14, G6-G19.
5. Bauer, H. H., & Fischer, M. (1998). Drug Life Cycles in the Pharmaceutical Industry, Empirical Detection and Consequences for R&D Profitability. Working paper #126, Institut für Marketing, University of Mannheim.
6. Berndt, E., Bui, L. T., Reiley, D. H., & Urban, G. L. (1994). The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the U.S. Anti-ulcer Drug Industry. Working Paper #19-94, Sloan School, MIT.
7. Bierly, P., & Chakrabarti, A. (1996). Determinants of technology cycle time in the U.S. pharmaceutical industry. R&D Management, 26, 115-126.
8. Bond, R. S., & Lean, D. F. (1977). Sales Promotion and Product Differentiation in Two Prescription Drug Markets. Washington, DC: Federal Trade Commission.
9. Bowman, D., & Gatignon, H. (1996). Order of entry as a moderator of the effect of the marketing mix on market share. Marketing Science, 15, 222-242.
10. Brockhoff, K. (1967). A test for the product life cycle. Econometrica, 35, 472-484.
11. Cox, W. E. (1967). Product life cycles as marketing models. Journal of Business, 40, 375-384.
12. Crask, M. R., & Perreault, W. D. Jr (1977). Validation of discriminant analysis in marketing research. Journal of Marketing Research, 14, 60-68.
13. Dant, R. P., Lumpkin, J. R., & Bush, R. P. (1990). Private physicians or walk-in clinics: Do the patients differ? Journal of Health Care Marketing, 10, 25-35.
14. Day, G. S. (1981). The product life cycle: Analysis and application issues. Journal of Marketing, 45, 60-67.
15. De Kluyver, C. A. (1977). Innovation and industrial product life cycles. California Management Review, 20, 21-33.
16. Dhalla, N. K., & Yuspeh, S. (1976). Forget the product life cylce concept! Harvard Business Review, 54, 102-111.
17. DiMasi, J. A. (1995). Success rates for new drugs entering clinical testing in the United States. Clinical Pharmacology and Therapeutics, 58, 1-14.
18. DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1995). Research and development costs for new drugs by therapeutic category. PharmacoEconomics, 7, 152-169.
19. DiMasi, J. A., Grabowski, H. G., & Vernon, J. M. (1995). R&D costs, innovative output and firm size in the pharmaceutical industry. International Journal of the Economics of Business, 2, 201-219.
20. DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10, 107-142.
21. Easingwood, C. J. (1988). Product life cycle patterns for new industrial goods. R&D Management, 18, 23-32.
22. Gardner, D. (1987). The product life cycle. Its role in marketing strategy. Die Unternehmung, 41, 219-231.
23. Gatignon, H., & Robertson, T. S. (1993). The impact of risk and competition on choice of innovations. Marketing Letters, 4, 191-204.
24. Golder, P. N., & Tellis, G. J. (1998). Is there life in the product life cycle? A study of consumer durables. Presentation, Marketing Science Conference 1998, Fontainebleau.
25. Grabowski, H. G., & Vernon, J. (1982). A sensitivity analysis of expected profitability of pharmaceutical research and development. Managerial and Decision Economics, 3, 36-40.
26. Grabowski, H. G., & Vernon, J. (1990). A new look at the returns and risks to pharmaceutical R&D. Management Science, 36, 804-821.
27. Grabowski, H. G., & Vernon, J. (1994). Returns to R&D on new drug introductions in the 1980s. Journal of Health Economics, 13, 384-406.
28. Graves, S. B., & Langowitz, N. S. (1993). Innovative productivity and returns to scale in the pharmaceutical industry. Strategic Management Journal, 14, 593-605.
29. Hair, J. F. Jr, Anderson, R. E., Tatham, R. L., & Black, W. C. (1992). Multivariate Data Analysis. (3rd Ed.). [New York].
30. Harrell, S. G., & Taylor, E. D. (1981). Modeling the product life cycle for consumer durables. Journal of Marketing, 45, 68-75.
31. Hoffmann, K. (1972). Der Produktlebenszyklus, Eine Kritische Analyse. Diss., Freiburg.
32. Huberty, C. J. (1984). Issues in the use and interpretation of discriminant analysis. Psychological Bulletin, 95, 156-171.
33. Jensen, R. (1982). Adoption and diffusion of an innovation of uncertain profitability. Journal of Economic Theory, 27, 182-193.
34. Jensen, E. J. (1987). Research expenditures and the discovery of new drugs. Journal of Industrial Economics, 36, 83-95.
35. Joglekar, P., & Patterson, M. L. (1986). A closer look at the returns and risks of pharmaceutical R&D. Journal of Health Economics, 5, 153-177.
36. Kalyanaram, G., & Urban, G. L. (1992). Dynamic effects of the order of entry on market share, trial penetration, and repeat purchases for frequently purchased consumer goods. Marketing Science, 11, 235-250.
37. Kalyanaram, G., Robinson, W. T., & Urban, G. L. (1995). Order of market entry: Established empirical generalizations, emerging empirical generalizations, and future research. Marketing Science, 14 (part 2 of No. 3), G212-G221.
38. Kaufmann, H., & Pape, H. (1984). Clusteranalyse. In L. Fahrmeir, & A. Hamerle, Multivariate Statistische Verfahren (pp. 371-473). [Berlin/New York].
39. Lachenbruch, P. A. (1967). An almost unbiased method of obtaining confidence intervals for the probability of misclassification in discriminant analysis. Biometrics, 23, 639-645.
40. Leone, R. P., & Schultz, R. L. (1980). A study of marketing generalizations. Journal of Marketing, 44, 10-18.
41. Mansfield, E. (1987). Price indexes for R&D inputs, 1969-1983. Management Science, 33, 124-129.
42. Mardia, K. V. (1971). The effect of nonnormality on some multivariate tests and robustness to nonnormality in the linear model. Biometrika, 58, 105-121.
43. Mattison, N., Trimble, A. G., & Lasagna, L. (1988). New drug development in the United States, 1963-1984. Clinical Pharmacology and Therapeutics, 43, 15-27.
44. Midgley, D. F. (1981). Toward a theory of the product life cycle: Explaining diversity. Journal of Marketing, 45, 109-115.
45. Milligan, G. W. (1980). An examination of the effect of six types of error pertubation on fifteen clustering algorithms. Psychometrika, 45, 325-342.
46. Milligan, G. W. (1981). A Monte Carlo study of thirty internal criterion measures for cluster analysis. Psychometrika, 46, 187-199.
47. Milligan, G. W., & Cooper, M. C. (1985). An examination of procedures for determining the number of clusters in a data set. Psychometrika, 50, 159-179.
48. Milligan, G. W., & Mahajan, V. (1980). A note on procedures for testing the quality of a clustering of a set of objects. Decision Sciences, 11, 669-677.
49. Myers, S. C., & Howe, C. D. (1997). A Life Cycle Financial Model of Pharmaceutical R&D. Working paper #41-97, MIT.
50. Myers, S. C., & Shyam-Sunder, L. (1996). Cost of capital estimates for pharmaceutical research and development. In R. D. Helms, Competitive Strategies in the Pharmaceutical Industry. Washington, DC: American Enterprise Institute.
51. Oren, S. S., & Schwartz, R. G. (1988). Diffusion of new products in risk-sensitive markets. Journal of Forecasting, 7, 273-287.
52. OTA: U.S. Congress, Office of Technology Assessment (1993). Pharmaceutical R&D: Costs, Risks, and Rewards. Washington: US Government Printing Office.
53. Parker, P., & Gatignon, H. (1994). Specifying competitive effects in diffusion models: An empirical analysis. International Journal of Research in Marketing, 11, S17-S39.
54. Polli, R. (1968). A Test of the Classical Product Life Cycle by Means of Actual Sales Histories. Ph.D. Dissertation, University of Pennsylvania.
55. Polli, R., & Cook, V. (1969). Validity of the product life cycle. Journal of Business, 42, 385-400.
56. Punj, G., & Stewart, D. W. (1983). Cluster analysis in marketing research: Review and suggestions for application. Journal of Marketing Research, 20, 134-148.
57. Rink, D. A., & Swan, J. E. (1979). Product life cycle research: A literature review. Journal of Business Research, 78, 219-242.
58. Robertson, T. S., & Gatignon, H. (1986). Competitive effects on technology diffusion. Journal of Marketing, July, S1-S12.
59. Sharma, S. (1996). Applied Multivariate Techniques. [New York].
60. Sheck, L., Cox, C., Davis, H. T., Trimble, A. G., Wardell, W. M., & Hansen, R. W. (1984). Success rates in the United States drug development system. Clinical Pharmacology and Therapeutics, 36, 574-583.
61. Steckel, J. H., & Vanhonacker, W. R. (1993). Cross-validating regression models in marketing research. Marketing Science, 12, 415-427.
62. Thorelli, H. B., & Burnett, S. C. (1981). The nature of product life cycles for industrial goods businesses. Journal of Marketing, 45, 97-108.
63. Urban, G. L., Carter, T., Gaskin, S., & Mucha, Z. (1986). Market share rewards to pioneering brands: An empirical analysis and strategic implications. Management Science, 32, 645-695.
64. Urban, G. L., & Hauser, J. R. (1993). Design and Marketing of New Products. (2nd Ed.). [New Jersey].
65. Wiggins, S. (1987). The Cost of Developing A New Drug. Washington, DC: Pharmaceutical Manufacturers Association.
66. Woltman, H. R. (1989). Reviewing the bidding: R&D costs and profitability of new chemical entities. Journal of Research in Pharmaceutical Economics, 1, 49-65.